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The physiopathology of gait and balance disorders in Parkinson’s disease patients is still poorly understood. Levodopa treat-
ment and subthalamic nucleus (STN) stimulation improve step length and walking speed, with less effect on postural instability.
These disorders have been linked to dysfunction of the descending basal ganglia outputs to brainstem structures. In this study,
we evaluated the effects of stimulation of the substantia nigra pars reticulata (SNr), on locomotion and balance in Parkinson’s
disease patients. Biomechanical parameters and leg muscle activity were recorded during gait initiation in seven selected
patients operated for bilateral STN stimulation, out of 204 stimulated patients, with one contact of each electrode located
within the SNr. Step length, anteroposterior and vertical velocities of the centre of gravity were studied, with special reference
to the subjects’ ability to brake the centre of gravity fall before foot-contact, and compared to seven controls. In Parkinson’s disease
patients, ﬁve treatment conditions were tested: (i) no treatment, (ii) levodopa treatment, (iii) STN stimulation, (iv) SNr stimulation
and (v) combined levodopa treatment and STN stimulation. The effects of these treatments on motor parkinsonian disability
were assessed with the UPDRS III scale, separated into ‘axial’ (rising from chair, posture, postural stability and gait) and ‘distal’
scores. Whereas levodopa and/or STN stimulation improved ‘axial’ and ‘distal’ motor symptoms, SNr stimulation improved only
the ‘axial’ symptoms. Compared to controls, untreated Parkinson’s disease patients showed reduced step length and velocity,
and poor braking just prior to foot-contact, with a decrease in both soleus (S) and anterior tibialis (AT) muscle activity. Step length
and velocity signiﬁcantly increased with levodopa treatment alone or in combination with STN stimulation in both natural and
fast gait conditions, and with STN stimulation alone in the fast gait condition. Conversely, SNr stimulation had no signiﬁcant
effect on these measures in either condition. In the natural gait condition, no fall in the centre of gravity occurred as step length
was low and active braking was unnecessary. In the fast gait condition, braking was improved with STN or SNr stimulation but
not with levodopa treatment, with an increase in the stance leg S muscle activity. These results suggest that anteroposterior
(length and velocity) and vertical (braking capacity) gait parameters are controlled by two distinct systems within the basal
doi:10.1093/brain/awn294 Brain 2009: 132; 172–184 | 172
Received May 21, 2008. Revised October 7, 2008. Accepted October 10, 2008. Advance Access publication November 11, 2008
 The Author (2008). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.
For Permissions, please email: journals.permissions@oxfordjournals.org
b
y
 
g
u
e
s
t
 
o
n
 
O
c
t
o
b
e
r
 
3
1
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 ganglia circuitry, representing respectively locomotion and balance. The SNr, a major basal ganglia output known to project to
pontomesencephalic structures, is postulated as being particularly involved in balance control during gait.
Keywords: Gait and balance; Parkinson’s disease; deep brain stimulation; substantia nigra; subthalamic nucleus
Abbreviations: AT=Anterior Tibialis; CG=Centre of Gravity; CP=Centre of Foot Pressure; GPi=Internal Part of the Globus
Pallidus; L=Step Length; MRI=Magnetic Resonance Images; PD=Parkinson’s Disease; PPN=Pedunculopontine Nucleus;
PSP=Progressive Supranuclear Palsy; S=Soleus; STN=Subthalamic Nucleus; SNr=Substantia Nigra Pars Reticulata; V1=Minimum
Vertical Velocity of the CG; V2=CG Vertical Velocity at Time of Foot-Contact; Vm=Maximum Anteroposterior Velocity of the CG
Introduction
The pathophysiology of gait and balance disorders in patients
with Parkinson’s disease is not fully understood. Parkinsonian
gait disorders consist of reduced walking speed and step length
(Blin et al., 1991; Giladi, 2001), start hesitation, freezing and
festination (Giladi et al., 2001). Postural instability compromises
the ability to maintain balance during everyday tasks and can
result in falls, which constitute a major public health problem
(Wenning et al., 1999; Bloem et al., 2001; Stolze et al., 2004).
Almost 50% of falls occur during walking, in particular during
the initiation and termination of gait (Ashley et al., 1977;
Masud and Morris, 2001). Gait is a dynamic and periodic process
during which loss and recovery of balance alternate. Because
two-thirds of human body mass is located two-thirds of body
height above the ground, body position would be inherently
unstable without a continuously active postural control system
(Winter, 1995). Walking can be thought of as being underpinned
by two different motor programmes: (i) the adoption of an erect
position and its maintenance when performing movements
that disturb the centre of gravity (CG) and (ii) the generation of
forward motion while stepping, in other words balance and
locomotion respectively. During the single support phase of gait
initiation, there is a falling phase in the CG, followed by a phase
of braking of the CG fall (hereafter referred to as ‘braking’). The
CG fall can be arrested by activation of the ankle plantar ﬂexors,
prior to foot-contact of the swing limb (‘active mode’), or by
the swing limb hitting the ground (‘passive mode’). The active
mode is used by normal adults (Welter et al., 2007). This vertical
impulse in the CG is altered when normal subjects are unbalanced
(Fiolkowski et al., 2002). The passive mode could reﬂect a
disruption of balance control as observed in patients with progres-
sive supranuclear palsy (PSP), a Parkinsonian neurodegenerative
disorder characterized by frequent early falls caused by severe
postural instability unresponsive to dopaminergic agents (Welter
et al., 2007), and in Parkinsonian patients suffering from postural
instability (Chastan et al., 2008). Gait and balance disorders
appear late in the course of Parkinson’s disease with long-term
aggravation and poor responsiveness to levodopa replacement
therapy suggesting that they may result from additional non-
dopaminergic lesions (Bonnet et al., 1987). In advanced forms
of Parkinson’s disease, high frequency stimulation of the sub-
thalamic nucleus (STN) or the internal part of the globus
pallidus (GPi), one of the two main outputs of the basal ganglia,
has been proposed with good postoperative outcome (Walter and
Vitek, 2004; Hamani et al., 2006; Kleiner-Fisman et al., 2006),
provided selection criteria are respected (Welter et al., 2002).
Recently, low frequency stimulation of the pedunculopontine
nucleus (PPN) region has been shown to improve Parkinsonian
gait and balance disorders similarly to high frequency STN stimu-
lation (Stefani et al., 2007) suggesting that these axial symptoms
are controlled, at least in part, by this mesencephalic structure.
In mammals, two mesencephalic structures involved in gait and
postural control have been described: the PPN and the mesence-
phalic locomotor region (MLR) or cuneiform nucleus (CNF)
(Takakusaki et al., 2003). These structures project efferent path-
ways to the lower brainstem and spinal cord and received affer-
ents inputs from basal ganglia structures (the substantia nigra
pars reticulata (SNr), the STN and the GPi), premotor and supple-
mentary motor cortical areas, and limbic system with hypothalamic
orexinergic system (Pahapill and Lozano, 2000; Takakusaki et al.,
2005). Excitatory projections from the hypothalamic orexinergic
system to mesencephalic structures facilitate locomotion. The
basal ganglia system receives its main inputs from cortical areas,
median nuclei of the thalamus and hippocampus (Obeso et al.,
2000). The basal ganglia system is involved in the selection,
planning and execution of learned motor programme such
as gait initiation and steady-state locomotion in human (Dietz,
1993). Two major descending basal ganglia pathways project
GABA inhibitory efferents to the PPN and the MLR (Takakusaki
et al., 2005). In animals, modulation of SNr activity, by micro-
injections of GABAergic agents, lesions or electrical stimulation,
modify both locomotion and postural control (Burbaud et al.,
1998; Takakusaki et al., 2003; Henderson et al., 2005).
However, to our knowledge, the SNr has never been deliberately
examined as a target for axial symptoms in Parkinson’s disease
patients (Bejjani et al., 1999; Caire et al., 2006). This paper
reports the effects of high frequency SNr stimulation on locomo-
tion and balance control during the gait initiation process, partic-
ularly the ability to brake the CG fall during stepping which
reﬂects postural control during gait, in seven Parkinsonian patients
operated for bilateral STN stimulation with electrode contacts
located within the SNr.
Methods
Patients
Between February 1996 and December 2005, 204 Parkinsonian
patients were operated for bilateral STN stimulation at the Pitie ´-
Salpe ˆtrie `re University Hospital, Paris. Electrodes were implanted in
a single operation under local anaesthesia using a target location
technique combining intra-operative recordings and stimulation,
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 as previously described (Bejjani et al., 2000a). The deﬁnitive quadri-
polar electrodes (Medtronic model 3389) were implanted bilaterally
into the STN. The precise anatomical localisation of stimulating con-
tacts was determined with reference to a digital atlas of the human
basal ganglia, in which anatomical contours are traced at the histo-
logical level of resolution with accurate 3D alignment. This atlas
(Yelnik et al., 2007) can be distorted in such a way as to adjust to
individual patient’s brains. Localisation of the electrodes and their
four contacts was determined in 145 patients by superimposing the
atlas sections on the postoperative magnetic resonance images (MRI)
obtained from each patient (Yelnik et al., 2003). From the sample
of 204 patients, 14 patients were retrospectively identiﬁed who
satisﬁed the criterion of at least one contact (always the most ventral
contact) of each quadripolar electrode located within the SNr (Fig. 1).
Three patients had died, two suffered dementia and could not there-
fore be included in this study and two others were unwilling to
participate. Finally, seven patients were included in this study (ﬁve
men, two women), age was 61.07.0 years [(meanSD), range=
50–68]. Mean disease duration was 18.34.2 years (13–20) and time
since STN stimulation was 43.620.1 months (20–72). The daily dose
of levodopa equivalent was 421252mg/day (100800). Thirteen
of the 14 therapeutic contacts were localized within the STN (seven in
the right and six in the left STN) and one therapeutic contact was
localised within the left Forel’s ﬁeld H2, leading to optimal clinical
improvement (Fig. 1). Seven, sex and age matched, control subjects
were also included (mean ageSD: 60.77.4 years). The study was
supported by the INSERM (RBM: 02–60), and approved by the local
Ethics Committee. All subjects gave informed written consent.
Test procedure
Clinical evaluation
Evaluation of motor disability in the Parkinson’s disease patients was
performed with the Uniﬁed Parkinson’s disease Rating Scale part III
(UPDRS III) (Fahn et al., 1987). The ‘axial’ score was deﬁned as the
sum of items 27–30 of the UPDRS III (rising from chair, posture,
postural stability and gait). The ‘distal’ score was deﬁned as the dif-
ference between the UPDRS III score and the ‘axial’ score without
the items 18, 19, 20 and 22 (speech, facial expression, lip tremor
and neck rigidity).
The patients were tested in ﬁve conditions: (i) ON STN stimulation/
OFF drug, using the chronic STN stimulation parameters and after a
night without anti-Parkinsonian medication; (ii) ON SNr stimulation/
OFF drug, after activation of the DBS stimulator on SNr contacts for
at least 1h (Fig. 1); (iii) OFF stimulation/OFF drug, after deactivation
of the DBS stimulator for at least 1h; (iv) OFF stimulation/ON drug,
after the administration of a single suprathreshold dose of levodopa
(identical to that used for the preoperative motor assessment, i.e.
with a 50mg more than the usual effective preoperative morning
dose); and (v) ON STN stimulation/ON drug, after activation of the
DBS stimulator using the chronic STN stimulation parameters with
levodopa treatment. The ﬁrst condition (ON STN stimulation/OFF
drug) was performed randomly either before (n=5) or after (n=2)
the second condition (ON SNr stimulation/OFF drug) to avoid order
effects. All ﬁve conditions were tested on the same day. STN stimula-
tion parameters were: monopolar cathodal using contact #3 (n=6), #2
(n=7) and #1 (n=1), where #3 was the most dorsal contact; pulse
width 60ms( n=12) and 90ms( n=2); mean stimulation frequency
159Hz (range: 130–190Hz); mean stimulation voltage 3.170.46V
(range: 2.2–3.7). SNr stimulation was monopolar cathodal using the
most ventral contact #0 in all patients (Fig. 1). Pulse width and stimu-
lation frequency were 60ms and 130Hz, respectively. SNr stimulation
intensity was progressively increased until the occurrence of persistent
adverse effects (brachiofacial dystonia (n=1), diplopia (n=4), heavi-
ness of eyelids (n=1), heaviness of lower limbs (n=1)), and then
reduced to 90% of this value. The meanSD intensity of SNr stimu-
lation was 2.50.68V (range: 1.4–3.5).
Gait initiation walking test
Subjects, barefoot and standing upright and motionless on a force
plate, were instructed to commence walking for 5m following a
beep delivered by the experimenter. Two experimental conditions
were tested: (i) the ‘natural’ gait condition where subjects walked
normally and (ii) the ‘fast’ gait condition where subjects walked
as fast as they could, taking large steps. Each subject performed
10 trials in each condition and was allowed to rest between trials.
Fig. 1 Localisation of STN and SNr stimulation contacts in
seven parkinsonian patients. (A) Atlas ‘morphed’ onto one
patient’s MRI. Left: Atlas contours from a sagittal postoperative
T1 MRI slice. Right: Atlas contours oriented along the axis of
the electrode. The caudate nucleus is represented in blue,
the STN in pink, the substantia nigra in black. The active
contact is yellow, the others are blue. The active contact is in
the STN and the most ventral contact is in the SNr. (B) Atlas
representation of the SNr (in grey) and STN (in pink). The
SNr contacts of all patients are represented by yellow cylinders.
The STN contacts of all patients are represented by blue
cylinders. SNr and STN are shown on oblique views showing
the longest axis of the left and the right SNr. The mean
coordinates of the two STN and SNr of the seven Parkinson’s
disease patients in relation to AC–PC coordinate system (mean
medio-lateral coordinateSD, mean dorso-ventral
coordinateSD, mean antero-posterior coordinateSD) were
for the right STN (10.590.56, 4.071.13, 9.750.79),
the left STN (11.751.2, 3.191.47, 10.721.77), the
right SNr (9.130.5, 7.110.62, 7.870.97) and the left
SNr (10.181.05, 6.660.53, 8.261.31).
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 The ‘natural’ and ‘fast’ gait conditions were assessed in the ﬁve
stimulation and treatment conditions described above.
Biomechanical analysis
Step length (L), peak progression velocity (Vm) of the ﬁrst step and
vertical velocity of the centre of gravity (CG) were measured (Fig. 2)
(Brenie `re and Bril, 1988; Welter et al., 2007). These variables were
obtained from a force platform (0.91.8m, Advanced Mechanical
Technology Inc LG6-4-1, USA) which provided continuous signals
proportional to the ground reaction forces (Rx, Ry, Rz in Newtons)
and moments (Mx, My, Mz in Newton metres) with respect to the
mediolateral (x), anteroposterior (y) and vertical (z) axes of the force
plate. The force plate analogue signals were digitized at 500Hz, CG
accelerations and velocities, and centre of foot pressure (CP) displace-
ments were calculated in real time using the Evolution
TM physiological
acquisition package (V3.5 Notocord SA, Croissy-sur-Seine, France).
Ofﬂine calculations were performed using custom-written VBA
macros after exporting the platform data to an Excel
TM workbook.
By dividing Mx by Rz, Ry by the subject’s body mass and (Rz—Body
Weight) by the body mass, we obtained respectively the anteropos-
terior displacement of the CP, the anteroposterior CG velocity and
vertical CG acceleration. L was measured from the anteroposterior
CP displacement corresponding to the distance between its initial posi-
tion (t0) and its position at the foot-off (FO2) time of the trailing
stance foot (Fig. 2, ﬁrst trace). The Vm of the CG reached at the
end of the ﬁrst step (Fig. 2, second trace) and the vertical velocity
of the CG were also measured (Fig. 2, third trace). In normal adults,
the vertical velocity of the CG curve is V shaped and displays negative
values during the swing phase, indicating that the CG is falling (the
CG fall is represented by V1, the minimum negative vertical velocity
Fig. 2 Biomechanical parameters and lower limb muscle activity during gait initiation in an individual control subject and a Parkinsonian
patient without levodopa treatment or stimulation (OFF stimulation/OFF drug), in natural and fast gait conditions. From top to bottom,
curves represent the anteroposterior displacement of the CP allowing the measurement of L, the anteroposterior velocity of the CG
with the measure of Vm, the vertical velocity of the CG, activities of anterior tibialis and S muscles of the stance and swing legs.
V1=minimum negative vertical velocity of the CG; V2=vertical velocity of the CG at foot contact; t0=ﬁrst detectable mechanical
displacement; FO=foot-off of the swing leg; FC=foot-contact of the swing leg; FO2=foot-off of the stance leg.
Nigral stimulation, gait and Parkinson’s disease Brain 2009: 132; 172–184 | 175
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 of the CG, i.e. the trough of the V). Before foot-contact, there is
a reversal of the CG fall and the vertical velocity of the CG increases
prior to foot-contact. At foot-contact, the vertical velocity of the
CG (V2) is then higher than the minimum vertical velocity of the
CG during the single support phase (V1), indicating that there is an
active braking of the CG fall before foot-contact. The increase in
the CG vertical velocity prior to foot-contact [(V1-V2)/V1
100] repre-
sents the subject’s ‘braking capacity’.
EMG recordings
The activity of both soleus (S) and anterior tibialis (AT) muscles was
simultaneously recorded bilaterally at a sampling rate of 5kHz using
bipolar surface electrodes. The EMG signals were ampliﬁed, band-pass
ﬁltered from 50Hz to 5kHz and rectiﬁed (Fig. 2, four lower traces).
Muscle activity was quantiﬁed by dividing the surface area of the
EMG amplitude proﬁle of each period by its duration. The integrated
EMG signal was quantiﬁed over three periods of gait initiation:
(i) during the anticipatory postural adjustment phase, between t0
and the foot-off; (ii) during the CG fall, between the foot-off
and the minimum negative vertical velocity of the CG (V1) and
(iii) during the braking of the CG fall, between the minimum negative
vertical velocity of the CG (V1) and foot-contact (Fig. 2).
Statistical analysis
The 10 trial means and standard deviations of ‘natural’ and ‘fast’ gait
conditions were calculated for each biomechanical parameter.
Similarly, the mean and standard deviations of the clinical measures
were calculated for each stimulation condition. The effects of levodopa
treatment, STN and SNr stimulation on Parkinsonian motor symptoms
and biomechanical parameters of gait were evaluated by comparing
the OFF stimulation/OFF drug condition with the other four stimula-
tion conditions (ON STN stimulation/OFF drug, ON SNr stimulation/
OFF drug, OFF stimulation/ON drug and ON STN stimulation/ON
drug), by means of the Wilcoxon matched pairs test. The differential
effects of STN and SNr stimulation on Parkinsonian motor symptoms
and gait parameters were assessed by means of the Wilcoxon matched
pairs test (ON STN stimulation/OFF drug versus ON SNr stimulation/
OFF drug). The relationship between Parkinsonian motor symptoms
and gait parameters was measured using the Spearman rank-correla-
tion test. The accepted signiﬁcance level was P50.05.
Results
Effects of levodopa treatment,
subthalamic or nigral stimulation
on Parkinsonian motor disability
In comparison to the OFF stimulation/OFF drug condition, the
Parkinsonian motor disability score (UPDRS III) improved signiﬁ-
cantly by 67% with levodopa treatment (P=0.03), 74% with STN
stimulation (P=0.02) and 85% with combined STN stimulation and
levodopa administration (P=0.03) with no signiﬁcant change with
SNr stimulation (Fig. 3A).
Fig. 3 Effects of levodopa treatment and STN or SNr stimulation on Parkinsonian motor disability (UPDRS III- A), axial (B), gait and
postural stability scores (C) in seven Parkinsonian patients. Parkinson’s disease patients were evaluated in ﬁve conditions: OFF=OFF
stimulation/OFF drug; L-DOPA=with levodopa treatment; STN=with subthalamic stimulation, SNr=with nigral stimulation, ON=with
combined levodopa treatment and STN stimulation. A and B: each symbol represents one subject.
P50.05 compared with the
condition OFF stimulation/OFF drug.
176 | Brain 2009: 132; 172–184 N. Chastan et al.
b
y
 
g
u
e
s
t
 
o
n
 
O
c
t
o
b
e
r
 
3
1
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 In comparison to the OFF stimulation/OFF drug condition, axial
symptoms improved signiﬁcantly with levodopa treatment (67%,
P=0.03), STN (49%, P=0.03) or SNr (44%, P=0.04) stimula-
tion, and with combined STN stimulation and levodopa adminis-
tration (78%, P=0.03) (Fig. 3B).
In comparison to the OFF stimulation/OFF drug condition, the
gait subscore improved signiﬁcantly by 81% with levodopa treat-
ment alone or in combination with STN stimulation (P=0.01),
and by 50% with STN or SNr stimulation (P=0.02, Fig. 3C left).
In comparison to the OFF stimulation/OFF drug condition, the
postural stability subscore improved signiﬁcantly with levodopa
treatment alone or in combination with STN stimulation (80%,
P=0.03), STN (50%, P=0.05) or SNr (60%, P=0.02) stimula-
tion alone (Fig. 3C right).
The ‘distal’ score improved signiﬁcantly by 68% with levodopa
treatment (P=0.03), 77% with STN stimulation (P=0.02), and
86% with combined STN stimulation and levodopa administration
(P=0.02). With SNr stimulation, the ‘distal’ score showed no
signiﬁcant change (15%, not shown).
In summary, our results show that bilateral SNr stimulation
signiﬁcantly improved only axial Parkinsonian motor symptoms
whereas bilateral STN stimulation signiﬁcantly improved global,
distal and, to a lesser degree, axial symptoms (Fig. 3, Table 1).
Biomechanical parameters of gait
initiation
In controls, the length and velocity of the ﬁrst step were 33%
and 40% greater in the fast compared to the natural gait condi-
tion (P50.001, Figs 2–4A). The minimum negative vertical velo-
city of the CG (V1), which represents the CG fall and the CG
vertical velocity at foot-contact (V2) were signiﬁcantly lower
(P50.01, Fig. 2), and the braking capacity was unchanged
between the two conditions (7%, P=0.29, Figs 2–4B). During
initiation of gait, the pattern of lower limb muscle activity was
similar in both natural and fast gait conditions (Fig. 2). The AT
muscle activity of both legs signiﬁcantly increased at the point
of the ﬁrst detectable movement (t0) and persisted during the
whole anticipatory postural adjustments phase, and decreased
during the CG fall and the braking phase (P50.005). The swing
leg AT muscle activity increased just before foot-contact. The
S muscle activity of the stance leg was minimal during the antici-
patory postural adjustments, increased signiﬁcantly during the CG
fall and increased again during the braking phase (P50.0001).
The S muscle activity of the swing leg increased signiﬁcantly
before foot-off, then decreased during CG fall and the braking
phase but increased just prior to foot-contact (Fig. 2).
In Parkinsonian patients (OFF stimulation/OFF drug condition),
the length and velocity of the ﬁrst step were signiﬁcantly lower
in the natural gait condition, compared to controls (P50.04,
Figs 2–4A left). In four patients, step length was 540cm and
consequently no CG fall occurred implying that braking before
foot-contact was unnecessary. In the fast compared to the natural
gait condition, length and velocity of the ﬁrst step signiﬁcantly
increased (+42% and +45%, respectively, P50.005, Figs 2–4A
right), whereas the CG fall (V1) and the vertical velocity at
foot-contact (V2) signiﬁcantly decreased (P50.005, Fig. 2).
Braking capacity was unchanged (25%, P=0.38) and was sig-
niﬁcantly lower than controls (P50.02, Figs 2–4B right).
Compared to controls, the pattern of lower limb EMG activity
was altered in Parkinsonian patients in the OFF stimulation/OFF
drug condition, both in the natural and fast gait conditions
(Fig. 2). In the stance leg, no signiﬁcant change in the AT activity
was observed during the whole gait initiation process. The activity
of the stance leg S muscle was signiﬁcantly lower during the CG
fall and braking phases. In the swing leg, the AT muscle was less
active during the anticipatory postural adjustment phase, before
foot-off, with no signiﬁcant change during the CG fall and braking
phases. In the swing leg S muscle, activity was signiﬁcantly lower,
with a relative preservation of the muscle activity pattern (Fig. 2).
Effects of levodopa treatment,
subthalamic or nigral stimulation
on biomechanical parameters of
gait in Parkinsonian patients
Step length
In the ‘natural’ gait condition, compared to the OFF stimulation/OFF
drug condition, L was 32% higher under levodopa treatment,
and 41% higher with combined STN stimulation and levodopa
treatment (P=0.02 in both cases). No signiﬁcant change in step
length was noted with either STN or SNr stimulation (Fig. 4A left).
In the ‘fast’ gait condition compared to the ‘natural’ gait con-
dition, step length was signiﬁcantly higher in all stimulation and
treatment conditions (Fig. 4A). In comparison to the OFF stimula-
tion/OFF drug condition, step length was higher by 12% under
levodopa treatment, 11% with STN stimulation, and 19% with
the combination of STN stimulation and levodopa treatment
(P=0.02 in all cases, Figs 4A, right–5). No signiﬁcant change in
the step length was observed with SNr stimulation.
Peak progression velocity
In the ‘natural’ gait condition, in comparison to the OFF stimulation/
OFF drug condition, the Vm was 33% greater under levodopa treat-
ment (P=0.03), and 40% greater with combined STN stimulation
Table 1 Summary of the effects of levodopa, STN and SNr
stimulation on clinical symptoms (distal and axial scores)
and biomechanical measures (step length, forward velocity
and the vertical parameter of braking)
Parkinsonian motor
symptoms
Gait initiation
biomechanical parameters
Distal Axial Length and
velocity
Braking
capacity
Levodopa + + + 0
STN stimulation + + + +
SNr stimulation 0 + 0 +
+=signiﬁcant improvement in comparison with the OFF stimulation/OFF drug
condition. 0=no signiﬁcant change in comparison with the OFF stimulation/OFF
drug condition.
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 and levodopa treatment (P=0.02) (Fig. 4A left lower graph).
No signiﬁcant change in Vm was observed with either STN or SNr
stimulation alone.
In the ‘fast’ compared to the ‘natural’ gait condition, Vm was
signiﬁcantly greater in all stimulation and treatment conditions
(Fig. 4A). In comparison to the OFF stimulation/OFF drug
condition, Vm was 14% greater under levodopa treatment
(P=0.03), 12% with STN stimulation (P=0.03), and 21% with
combined STN stimulation and levodopa treatment (P=0.02)
(Fig. 4A right lower graph–5). There was no signiﬁcant change
in the maximum peak velocity with SNr stimulation alone.
CG fall and braking capacity
In the natural gait condition, in comparison to the OFF stimula-
tion/OFF drug condition, the minimum negative vertical velocity
of the CG (V1) was signiﬁcantly lower under levodopa treatment,
STN stimulation alone or in combination with levodopa treatment
(P50.005). As four patients had step lengths540cm in all natural
gait stimulation and treatment conditions (Fig. 5), with in conse-
quence only a slight CG fall, the braking capacity in all stimulation
and treatment conditions could therefore only be measured in the
‘fast’ gait condition.
In the ‘fast’ gait condition compared to the OFF stimulation/
OFF drug condition, no signiﬁcant change in the CG fall (V1) and
the vertical velocity of the CG at foot-contact (V2) was observed
in any of the treatment and stimulation conditions (Fig. 5). STN
or SNr stimulation signiﬁcantly improved the degree of braking in
comparison to the OFF stimulation/OFF drug condition (V2-V1,
+71% and +99%, respectively) (Fig. 4b upper right graph) and
the braking capacity (+41% and +86%, respectively) (Figs 4b
lower right graph–5), whereas levodopa treatment with or without
STN stimulation induced no signiﬁcant change in braking capacity.
Lower limb EMG activity
In the stance leg, compared to the OFF stimulation/OFF drug
condition, the TA muscle activity did not change signiﬁcantly
with levodopa treatment, STN or SNr stimulation (Figs 5 and 6A
left). The S muscle activity however was signiﬁcantly higher during
STN stimulation within both the CG fall (FO1-V1) and braking
(V1-V2) phases, and increased with SNr stimulation during the
braking phase, in particular in patients showing improved braking
capacity (Figs 5–6A right). In the swing leg, comparison with
the OFF stimulation/OFF drug condition, showed no signiﬁcant
change in either TA and S muscle activity with either levodopa
treatment, STN or SNr stimulation (Fig. 6B).
In summary, SNr stimulation improved only the vertical bio-
mechanical measure of braking capacity with an increase in the
S activity of the stance leg during the braking phase whereas
STN stimulation improved both the anteroposterior and vertical
biomechanical parameters of gait initiation, with an increase in
Fig. 4 Effects of levodopa treatment and STN or SNr stimulation on length and velocity of the ﬁrst step (A) and braking capacity
(B) in seven Parkinsonian patients, in both natural and fast gait conditions. (C) controls. Parkinson’s disease patients were evaluated in
ﬁve conditions: OFF=OFF stimulation/OFF drug; L-DOPA=with levodopa treatment; STN=with subthalamic stimulation; SNr=with
nigral stimulation; ON=with combined levodopa treatment and STN stimulation. Each symbol represents one subject.
+P50.05
when compared OFF stimulation/OFF drug PD patients with controls.
P50.05 compared with the condition OFF stimulation/OFF
drug.
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 the S activity of the stance leg during the execution of the ﬁrst
step (Table 1).
Relationship between motor
Parkinsonian symptoms and
biomechanical gait parameters
The ‘axial’ score was signiﬁcantly negatively correlated with
L( r=0.7P50.0001 and r=0.6P=0.0002 respectively),
Vm (r=0.4P=0.001 and r=0.5P=0.001 respectively) and
degree of braking (V2-V1) (r=0.6P=0.001 and r=0.3
P=0.04 respectively) in both the ‘natural’ and ‘fast’ gait condi-
tions. No signiﬁcant correlation was found between the ‘distal’
score and either the length, Vm of the ﬁrst step or the degree
of braking.
Discussion
This study showed that, in Parkinson’s disease patients, bilateral
SNr stimulation improves axial Parkinsonian motor symptoms (gait
and balance disorders) and braking capacity of the CG fall but
has no effect on distal Parkinsonian motor symptoms (segmental
akinesia, rigidity and tremor) and anteroposterior biomechanical
parameters of gait (length and velocity of the ﬁrst step).
Conversely, STN stimulation improves both distal and axial
Parkinsonian motor symptoms and both anteroposterior and ver-
tical biomechanical parameters of gait (Table 1).
These results are robust as the group of Parkinson’s disease
patients was homogeneous and carefully selected (Welter et al.,
2002), using identical neurosurgical procedures. All Parkinson’s
disease patients were evaluated by the same experimenter,
Fig. 5 Effects of levodopa treatment and STN or SNr stimulation on biomechanical gait parameters in an individual Parkinsonian
patient, in the fast gait condition. Same legend as Fig. 2.
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 under the same conditions, with postoperative OFF stimulation/
OFF drug Parkinsonian motor scores similar to those obtained
before surgery without levodopa treatment (OFF drug, Fig. 3).
The location of the electrode contacts was determined using a
reliable, validated method (Yelnik et al., 2003) and 13 STN and
all SNr (n=14) contacts were similarly placed (Fig. 1B). One STN
therapeutic contact was located in Forel’s ﬁeld H2, stimulation
of this structure has been demonstrated to have a similar clinical
effect to STN stimulation, however (Vergani et al., 2007). In the
substantia nigra, stimulation was conﬁned to the pars reticulata
(Fig. 1B). Lastly, it is unlikely that current spread from STN stimu-
lation could have inﬂuenced the SNr or vice versa as (i) the STN
contacts used in our patients were separated from those in the
STN by at least 4mm in 13 of the 14 electrodes of our seven
Parkinson’s disease patients (6mm for six contacts, 4mm for
seven contacts), and only by 2mm in one electrode and (ii) it
has been previously shown that a 3V monopolar stimulation
can activate axonal elements within a radius of 2.5mm from
the centre of the electrode contact (Wu et al., 2001) with a
maximum of 4mm when the electrode is localized within the
STN, taking into account tissue electrical properties (McIntyre
et al., 2004). For all these reasons, we consider the results of
this study to be reliable despite the small patient sample (n=7).
However, this number could not be increased despite the analysis
of the electrode positions of 204 patients implanted at our
centre, in which only a small number of patients could be found
with implanted bilateral electrode contacts selectively located
within the SNr.
Fig. 6 Effects of levodopa treatment and STN or SNr stimulation on lower limb muscle activity in seven Parkinsonian patients. The
same symbol for each subject as in Figs 3 and 4.
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 Effects of subthalamic high frequency
stimulation and levodopa treatment
It has been shown previously that Parkinsonian motor distal and
axial symptoms are both improved under levodopa replacement
therapy or STN stimulation (Limousin et al., 1998; Bejjani et al.,
2000b; Krack et al., 2003; Schupbach et al., 2005). Similarly,
length and velocity of the ﬁrst step (anteroposterior gait initiation
parameters) increase with these two treatments (Blin et al., 1991;
Azulay et al., 1996; Allert et al., 2001; Faist et al., 2001; Stolze
et al., 2001; Bastian et al., 2003) (Fig. 3A), with an improvement
in the asymmetry of gait, single and double support times and
progression of the CP (Allert et al., 2001). This suggests that
reduced length and velocity of the ﬁrst step result mainly from
the decreased dopaminergic transmission characteristic of the
disease, in line with data obtained in mice with MPTP-induced
degeneration of nigro-striatal dopamine transmission (Fernagut
et al., 2002). Postural control is altered in Parkinson’s disease
patients with an increase in postural oscillations during quiet
standing (Mitchell et al., 1995; Rocchi et al., 2004). Subthalamic
stimulation has been shown to improve postural control in a static
position (Rocchi et al., 2004; Colnat-Coulbois et al., 2005) and
during gait initiation, with a reduction in the imbalance phase
and a larger anteroposterior and mediolateral displacement of
the CP during anticipatory postural adjustments (Crenna et al.,
2006). In this study, the braking capacity of the CG fall was not
signiﬁcantly altered by levodopa treatment, while STN stimulation
improved it (Fig. 4B). This suggests that this gait initiation process,
i.e. the braking capacity, which could reﬂect postural control
during gait (Welter et al., 2007), is not directly controlled by
brain dopaminergic systems but is dependent upon basal ganglia
activity, in particular that of the STN. The fact that this mechan-
ism is severely altered in PSP patients (Welter et al., 2007) who
showed severe degeneration of STN neurons (Hauw et al., 1994;
Litvan et al., 1996) is in line with this hypothesis.
Effects of SNr high frequency
stimulation
High frequency stimulation of the SNr dramatically improved
axial, but not distal, Parkinsonian motor symptoms (Fig. 3), with
an increase in braking capacity (Figs 3A–4). These SNr stimulation
effects are in line with observations of severe axial postural ano-
malies induced by injections of GABAergic agents into the SNr
of normal primates (Burbaud et al., 1998) and reversal of body
orientation changes in primates rendered Parkinsonian by SNr
lesions, without improvement of the bradykinesia on the centrolat-
eral side (Henderson et al., 2005). As in our study performed in
humans, these data suggest that in primates the SNr is primarily
involved in postural control. However, injections of GABA antago-
nists into the SNr of monkeys rendered hemi-Parkinsonian show
different results depending on the injection site (Wichmann et al.,
2001). Centrolateral SNr injection was found to improve both
akinesia and bradykinesia, whereas medial SNr injections induced
strong behavioural activation, turning and dystonia-like neck and
body postures with no effect on limb mobility. In our patients,
stimulation was conﬁned to the medial SNr (Fig. 1B), a result
which is in agreement with the effects of injections of GABA antago-
nists in experimental animals. SNr stimulation increased braking
capacity with no signiﬁcant effect on length and velocity of the
ﬁrst step suggesting that SNr controls, at least partly, the braking
mechanism, which is thought to reﬂect the control of balance
during gait (Welter et al., 2007). This increase in the capacity to
brake the CG fall could result from an increase in the activity of
the stance leg S muscle as observed in our patients (Fig. 6A) with
an increase in the CG vertical impulse prior to foot landing (Brenie `re
and Bril, 1988). This is in agreement with modulations of both
muscle tone inhibitory and locomotion executing systems induced
by high frequency (100Hz) electrical stimulation of the SNr in
primates (Takakusaki et al., 2003).
Subthalamic versus nigral high
frequency stimulation
High frequency STN stimulation improved both distal and axial
mobility whereas SNr stimulation improved only axial motor symp-
toms. This suggests that the SNr output participates in axial, but
not distal, motor control, whereas the STN is involved in both. SNr
efferents ascend to the thalamus, but also descend to the brain-
stem, in particular to the pontomesencephalic area which is known
to be involved in locomotion and postural control (Takakusaki
et al., 2003). According to the classic basal ganglia functional
model, the STN nucleus projects excitatory inputs to both the
SNr and the internal segment of the GPi, the two main basal
ganglia outputs (Alexander et al., 1990). Previous studies have
shown that GPi stimulation improves Parkinsonian motor disability
(Krack et al., 1998; Volkmann et al., 2001; Anderson et al.,
2005), with less improvement in axial symptoms (Krack et al.,
1998; Allert et al., 2001; Rodriguez-Oroz et al., 2005), suggesting
that GPi stimulation preferentially improves motor Parkinsonian
distal symptoms. From a neurophysiological point of view, we
observed a similar dichotomy with an improvement of both ante-
roposterior and vertical gait initiation parameters with STN stimu-
lation whereas SNr stimulation only improves vertical measures,
i.e. the CG fall braking capacity. Unfortunately it was not possible
to examine Parkinson’s disease patients with bilateral pallidal
stimulation in our centre. Pallidal stimulation has been reported
to improve step length and velocity of the ﬁrst step with a
decrease in double support time and an increase in single support
time (Krystkowiak et al., 2001; Defebvre et al., 2002), although
with a smaller effect than with STN stimulation (Allert et al.,
2001). Pallidal stimulation had less effect on postural control
with no signiﬁcant change in CP displacements during anticipatory
postural adjustments (Defebvre et al., 2002) and a larger vari-
ability in CP displacement during quiet standing (Rocchi et al.,
2004). This suggests that STN stimulation induces a decrease
in both distal and axial Parkinsonian motor symptoms and both
anteroposterior and vertical parameters of gait initiation by its
effects on both GPi and SNr neuronal activity (Hashimoto et al.,
2003; Malte ˆte et al., 2007), whereas stimulation of the SNr
only modulates SNr activity with a consequent decrease in axial
motor symptoms and an improvement in vertical gait parameters.
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 Both SNr and STN project ascending efferents, via the GPi and
the SNr for the STN, to the thalamus which projects inhibitory
efferents to cortical areas (Alexander et al., 1990). Improvement
in axial motor symptoms and vertical gait parameters could thus
result from changes in cortical activity. Using functional imaging
and neurophysiological approaches, it has been shown that
STN stimulation normalizes cortical activity related to the control
of movement (Devos et al., 2004), in particular in the supplemen-
tary motor area (Grafton et al., 2006). Recently, a relationship
between improvement in freezing of gait and metabolic activity
of the parietal, occipital and temporal sensory association cortices
has been reported (Lyoo et al., 2007).
Role of the mesopontine tegmental
structures in the braking mechanism
In addition to their ascending efferent pathways, both STN and
SNr project descending efferents to the mesopontine tegmental
area, with GABAergic inhibitory inputs to the PPN and the CNF
for the SNr, and glutamatergic excitatory inputs to the PPN for the
STN (Obeso et al., 2000). In animals, these two structures, located
in mesopontine tegmentum, have been shown to be widely impli-
cated in the control of postural muscle tone and locomotion
(Prentice and Drew, 2001; Takakusaki et al., 2003). In decerebrate
cats, activation of the CNF (which is part of the so-called midbrain
locomotion region or MLR) increases muscle tone and induces
locomotion when animals are placed on a moving treadmill
(Takakusaki et al., 2003). Activation of the ventral PPN is required
to initiate locomotion (Garcia-Rill, 1991) and suppresses postural
muscle tone (Takakusaki et al., 2003). In Parkinson’s disease,
it is thought that the GABAergic inhibitory inputs are overactive
with an excessive inhibition of the MLR with gait failure and of the
PPN with an increase in the level of muscle tone. High frequency
stimulation of the SNr may reduce this excess inhibition by indu-
cing a reduction of the SNr neuronal activity, as reported in the
STN with during STN stimulation (Welter et al., 2004), resulting
in an increase in the braking mechanism and decrease in gait
and balance disorders in Parkinson’s disease patients (this study).
The fact that a dramatic alteration of the braking mechanism
has been observed in PSP patients (Welter et al., 2007), who
show a loss of PPN neurons (Hirsch et al., 1987), and in
Parkinson’s disease patients with levodopa unresponsive postural
instability and mesencephalic area atrophy is in line with this
hypothesis. Recently, low frequency PPN stimulation (which is
thought to activate PPN neurons) has been reported to improve
gait impairment and postural instability in Parkinson’s disease
patients (Stefani et al., 2007), with modulation of spinal excitabil-
ity (Pierantozzi et al., 2008). In contrast to high frequency SNr
stimulation, low frequency PPN stimulation also improves non-
axial Parkinsonian motor symptoms, presumably as a result of
the ascending PPN projections to the STN and the GPi (Pahapill
and Lozano, 2000).
Conclusion
SNr stimulation improves clinical axial symptoms but not distal
ones. We propose that the SNr and GPi basal ganglia outputs
map separately onto the downstream motor systems controlling
these two aspects of PD symptomatology. Whereas SNr output
principally inﬂuences axial movement (but not distal), the GPi
output inﬂuences, at least, distal movement, with the STN inﬂuen-
cing both because of its projections to the two output nuclei.
Vertical biomechanical analysis obtained using a force platform
is a new tool for the study of postural control during gait. Our
stimulation results imply that the SNr output is involved in the
braking mechanism probably as a result of its projection to
the PPN. Since the SNr is located just underneath the STN and
because during the normal surgical procedure for STN electrode
implantation, the SNr is usually targeted for electrophysiological
recordings, the SNr could be envisaged as a complementary thera-
peutic target in Parkinson’s disease patients selected for surgery
for the treatment of gait and balance disorders. However, further
investigation will be required to determine the effects of combined
STN and SNr stimulation in Parkinson’s disease patients with axial
motor impairment.
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